Compare LDOS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LDOS | RVMD |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | 47000 | 883 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 19.2B |
| IPO Year | 2005 | N/A |
| Metric | LDOS | RVMD |
|---|---|---|
| Price | $149.14 | $147.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | ★ $203.15 | $140.84 |
| AVG Volume (30 Days) | 708.9K | ★ 3.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 20.82 | N/A |
| EPS | ★ 11.14 | N/A |
| Revenue | ★ $17,174,000,000.00 | N/A |
| Revenue This Year | $6.50 | N/A |
| Revenue Next Year | $4.40 | $533.02 |
| P/E Ratio | $13.39 | ★ N/A |
| Revenue Growth | ★ 3.07 | N/A |
| 52 Week Low | $139.69 | $34.00 |
| 52 Week High | $205.77 | $155.70 |
| Indicator | LDOS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 64.70 |
| Support Level | N/A | $93.39 |
| Resistance Level | $161.39 | $155.70 |
| Average True Range (ATR) | 3.71 | 7.32 |
| MACD | 0.30 | -0.47 |
| Stochastic Oscillator | 33.12 | 64.71 |
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health management, both domestically and internationally. The customers of the company includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.